Skip to main content
OpenTrials

Clinical trial condition

Refractory Primary Central Nervous System Neoplasm

Explore clinical trials studying Refractory Primary Central Nervous System Neoplasm. Study availability and eligibility vary by location and protocol.

18 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Refractory Primary Central Nervous System Neoplasm trial results

Completed

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

NCT02780804

Conditions
Brain Diseases, Brain Neoplasms, Brain Stem Neoplasm, +30 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Children's Hospital of Orange County Orange, California, United States
  • UCSF Medical Center-Mission Bay San Francisco, California, United States
View all 21 locations
View Trial Details
Completed

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

NCT02415153

Conditions
Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cranial Nerve Diseases, +33 more
Locations
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States
  • Children's National Medical Center Washington D.C., District of Columbia, United States
  • Lurie Children's Hospital-Chicago Chicago, Illinois, United States
View Trial Details
Active, Not Recruiting

Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

NCT03598244

Conditions
Brain Diseases, Brain Neoplasms, Brain Stem Neoplasms, +25 more
Locations
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States
  • Children's Hospital Colorado Aurora, Colorado, United States
  • Children's National Medical Center Washington D.C., District of Columbia, United States
View Trial Details
Active, Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620

Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, +99 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 172 locations
View Trial Details
Active, Not Recruiting

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

NCT02867592

Conditions
Adenocarcinoma, Adrenal Cortex Diseases, Adrenal Cortex Neoplasms, +92 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Kaiser Permanente-Anaheim Anaheim, California, United States
View all 142 locations
View Trial Details
Active, Not Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

NCT03213652

Conditions
Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +82 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 126 locations
View Trial Details
Active, Not Recruiting

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

NCT03213704

Conditions
Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +83 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 124 locations
View Trial Details
Active, Not Recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

NCT03210714

Conditions
Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +74 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 116 locations
View Trial Details

Related conditions